Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm-Reference-Cited by-同舟云学术

Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm

Published:2017-08-01 Issue:suppl_4 Volume:56 Page:iv30-iv48
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:

Author:

Schulze-Koops Hendrik¹,Skapenko Alla¹

Affiliation:

1. Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians-University of Munich, Munich, Germany

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/56/suppl_4/iv30/24245874/kex277.pdf

Reference67 articles.

1. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and meta-analysis;Gartlehner;J Rheumatol,2006

2. American College of Rheumatology/Spondyloarthritis Research and Treatment Network 2015. Recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis;Ward;Arthritis Rheumatol,2016

3. The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics;Coates;Rheumatology,2013

4. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009;Smith;Br J Dermatol,2009

5. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis;Braun;Ann Rheum Dis,2011

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imbalanced machine learning classification models for removal biosimilar drugs and increased activity in patients with rheumatic diseases;PLOS ONE;2023-11-30

2. Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview;Expert Opinion on Drug Metabolism & Toxicology;2023-10-25

3. The landscape of biosimilars in Saudi Arabia: preparing for the next decade;Expert Opinion on Biological Therapy;2023-07-28

4. Experience of Mass Switching to Biosimilar Drugs in Patients with Immune-Mediated Inflammatory Rheumatic Diseases. Effectiveness and Safety. Intercambiosim Project;2023-07-20

5. Juvenile Idiopathic Arthritis;Orthopaedics for the Newborn and Young Child;2023